Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review

Objectives: Co-occurring substance use disorders (SUDs) among individuals with schizophrenia are a prevalent and complex psychiatric comorbidity, which is associated with increased symptom severity, worsened illness trajectory and high rates of treatment non-adherence. Recent evidence suggests that...

Full description

Bibliographic Details
Main Authors:	Alexandria S. Coles, Dunja Knezevic, Tony P. George, Christoph U. Correll, John M. Kane, David Castle
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-12-01
Series:	Frontiers in Psychiatry
Subjects:	schizophrenia substance use disorder (SUD) long acting injectable (LAI) antipsychotic treatment
Online Access:	https://www.frontiersin.org/articles/10.3389/fpsyt.2021.808002/full

Similar Items

Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications
by: Anuradha Baminiwatta, et al.
Published: (2023-06-01)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
by: Christoph U. Correll, et al.
Published: (2022-01-01)

Psychological and Psychopharmacological Interventions in Psychocardiology
by: Kai G. Kahl, et al.
Published: (2022-03-01)

Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists
by: Christoph U. Correll, et al.
Published: (2019-11-01)

Antipsychotic effects on anthropometric outcomes in anorexia nervosa: a retrospective chart review of hospitalized children and adolescents
by: Bettina Frank, et al.
Published: (2023-09-01)

Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery
by: Celso Arango, et al.
Published: (2023-06-01)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
by: Correll Christoph U, et al.
Published: (2008-04-01)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
by: Daniel Schöttle, et al.
Published: (2018-11-01)

Combination of Two Long-Acting Antipsychotics in Schizophrenia Spectrum Disorders: A Systematic Review
by: Salvatore Cipolla, et al.
Published: (2024-04-01)

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis
by: Koen Demyttenaere, et al.
Published: (2022-04-01)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
by: Sajatovic M, et al.
Published: (2018-06-01)

The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach
by: Christoph U. Correll, et al.
Published: (2022-01-01)

Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study
by: Ramandeep Kaur, et al.
Published: (2023-04-01)

Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs
by: Julia M Gohlke, et al.
Published: (2012-06-01)

The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index
by: Daniel Schöttle, et al.
Published: (2020-02-01)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
by: Litman R, et al.
Published: (2023-01-01)

Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
by: M. Lähteenvuo, et al.
Published: (2021-04-01)

The relationship between combined antipsychotic use and clinical features in schizophrenia spectrum patients treated in inpatient ward: A retrospective study
by: U. Baklaci
Published: (2021-04-01)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
by: Lopez A, et al.
Published: (2019-02-01)

Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient–Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care
by: Correll CU, et al.
Published: (2024-10-01)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
by: Chiu LL, et al.
Published: (2019-07-01)

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
by: Sajatovic M, et al.
Published: (2018-06-01)

Adaptation of a peer based online emotional support program as an adjunct to treatment for people with schizophrenia-spectrum disorders
by: Amit Baumel, et al.
Published: (2016-05-01)

Reducing Addiction in Bipolar Disorder via Hacking the Dopaminergic System
by: Heinz Grunze, et al.
Published: (2021-12-01)

Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly
by: Christoph U. Correll, et al.
Published: (2023-11-01)

Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report
by: Muneto Izuhara, et al.
Published: (2018-06-01)

Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
by: Fredrik Hieronymus, et al.
Published: (2021-08-01)

Study of factors associated with obesity in patients using antipsychotics in schizophrenia
by: Vishalakshi Patnam, et al.
Published: (2024-12-01)

Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia
by: Kristian S. Hill, et al.
Published: (2009-04-01)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
by: Hiroyuki Kamei
Published: (2022-11-01)

antipsychotics and metabolic syndrome
by: R. Jomli, et al.
Published: (2022-06-01)

Atypical antipsychotics in the treatment of schizophrenia
by: Swiss Medical Weekly
Published: (2003-02-01)

Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-08-01)

What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia
by: Christoph U. Correll, et al.
Published: (2024-07-01)

Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
by: Christoph U. Correll, et al.
Published: (2022-02-01)

Erectile dysfunction among male patients diagnosed with schizophrenia being treated with antipsychotic medication, and the impact on quality of life
by: W. W. J. S. M Rowel, et al.
Published: (2018-12-01)

Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics
by: Hikaru Hori, et al.
Published: (2022-05-01)

Which antipsychotics can we use for obsessive-compulsive symptoms in schizophrenia?
by: A. Aissa, et al.
Published: (2021-04-01)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
by: P. Ifteni, et al.
Published: (2021-04-01)

The Effect of Antipsychotics on Cognition in Schizophrenia—A Current Narrative Review
by: Petru Fabian Lungu, et al.
Published: (2024-04-01)